Browsing Tag
KST-6051
1 post
Can KST-6051 unlock broader KRAS cancer treatment beyond G12C inhibitors
KST-6051 enters Phase 1 with AbbVie Inc. backing. Discover how pan-KRAS inhibitors could expand treatment across KRAS-driven cancers.